Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 85; no. 2; pp. 306 - 313
• Main Authors: Joerger, M, Baty, F, Früh, M, Droege, C, Stahel, R.A, Betticher, D.C, von Moos, R, Ochsenbein, A, Pless, M, Gautschi, O, Rothschild, S, Brauchli, P, Klingbiel, D, Zappa, F, Brutsche, M
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ireland Ltd 01.08.2014; Elsevier
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Biological and medical sciences; Biomarkers; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Combined Modality Therapy; Disease Progression; Erlotinib; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Hematology, Oncology and Palliative Medicine; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Medical sciences; MicroRNA's; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Neoplasm Staging; Platinum - administration & dosage; Pneumology; Prognosis; Prospective Studies; Pulmonary/Respiratory; Quinazolines - administration & dosage; Reproducibility of Results; Risk Factors; Tumors; Tumors of the respiratory system and mediastinum; MicroRNA's; Biomarkers; Chemotherapy; Erlotinib; Lung cancer; Bevacizumab; Antineoplastic agent; Human; Lung disease; Prognosis; Respiratory disease; Biological marker; Patient; Malignant tumor; Cisplatin; Treatment; Platinum; Carboplatin; Bronchus disease; Evolution; Advanced stage; Cancer; Non small cell carcinoma
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2014.04.014

Highlights • We performed extensive micro-RNA profiling in 50 patients with advanced NSCLC. • Patients received erlotinib/bevacizumab followed by chemotherapy at progression. • Micro-RNA profiling was performed in peripheral blood samples at start of treatment. • Six micro-RNA's were significantly and independently associated with survival. • High expression of micro-RNA 29a was associated with a markedly decreased survival.